Heplofit Tablet is a pharmaceutical formulation containing L-Ornithine L-Aspartate (150 mg) and Pancreatin (100 mg), indicated for the management of hepatic encephalopathy and digestive enzyme insufficiency. L-Ornithine L-Aspartate acts by facilitating the detoxification of ammonia through the urea cycle, thereby reducing elevated blood ammonia levels commonly observed in patients with liver dysfunction. This mechanism helps improve cognitive function and neurological symptoms associated with hepatic encephalopathy. Pancreatin, a combination of digestive enzymes including amylase, lipase, and protease, aids in the digestion and absorption of nutrients by compensating for pancreatic enzyme deficiency, which is often seen in chronic pancreatitis and other exocrine pancreatic insufficiencies. The synergistic action of these components supports both liver detoxification processes and digestive function, promoting overall gastrointestinal health. Heplofit Tablet is typically administered orally, with dosage and duration tailored according to clinical condition and physician guidance. It is contraindicated in patients with hypersensitivity to any component and should be used cautiously in individuals with severe renal impairment. Common adverse effects may include gastrointestinal discomfort and allergic reactions. Regular monitoring of liver function and ammonia levels is recommended during therapy to assess efficacy and safety.